Blueprint Medicines Q2 2024 GAAP EPS $(0.80) Beats $(1.30) Estimate, Sales $138.157M Beat $103.575M Estimate
Author: Benzinga Newsdesk | August 01, 2024 07:09am
Blueprint Medicines (NASDAQ:
BPMC) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.30) by 38.46 percent. The company reported quarterly sales of $138.157 million which beat the analyst consensus estimate of $103.575 million by 33.39 percent. This is a 139.98 percent increase over sales of $57.570 million the same period last year.
Posted In: BPMC